Phase II Trial of Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 入组人数
- 71
- 试验地点
- 2
- 主要终点
- Percentage of Recipients Who Are Alive With >50% Donor T Cell Chimerism and Graft-failure Free at 180 Days Post Hematopoietic Cell Transplant (HCT) Reported With an 80% Confidence Interval
研究概览
简要总结
Background:
Blood stem cells in the bone marrow make all the cells to normally defend a body against disease. Allogeneic blood or marrow transplant is when these stem cells are transferred from one person to another. Researchers think this treatment can provide a new, healthy immune system to correct T-cell problems in some people.
Objective:
To see if allogeneic blood or bone marrow transplant is safe and effective in treating people with T-cell problems.
Eligibility:
Donors: Healthy people ages 4 and older
Recipients: People the same age with abnormal T-cell function causing health problems
Design:
All participants will be screened with:
- Medical history
- Physical exam
- Blood, heart, and urine tests
Donors will also have an electrocardiogram and chest x-ray. They may have veins tested or a pre-anesthesia test.
Recipients will also have lung tests.
Some participants will have scans and/or bone marrow collected by needle in the hip bones.
Donors will learn about medicines and activities to avoid and repeat some screening tests.
Some donors will stay in the hospital overnight and have bone marrow collected with anesthesia.
Other donors will get shots for several days to stimulate cells. They will have blood removed by plastic tube (IV) in an arm vein. A machine will remove stem cells and return the rest of the blood to the other arm.
Recipients will have:
- More bone marrow and a small fragment of bone removed
- Dental, diet, and social worker consultations
- Scans
- Chemotherapy and antibody therapy for 2 weeks
- Catheter inserted in a chest or neck vein to receive donor stem cells
- A hospital stay for several weeks with more medicines and procedures
- Multiple follow-up visits
详细描述
Background:
- Disorders of T-cell proliferation and/or dysregulation (TCP/D) can lead to T-cell lymphoproliferative disorders, autoimmunity, infection, and aberrant immune activation with resulting organ dysfunction, morbidity, and mortality.
- Allogeneic hematopoietic cell transplantation (HCT) has the potential to cure disorders of TCP/D.
- Subjects with TCP/D may be at higher risk for graft rejection and/or disease relapse.
Primary Objective:
- Separately by arm: To estimate the percentage of recipients with >50% donor T cell chimerism and graft-failure free survival at day +180 post-HCT
Eligibility:
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 4 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •INCLUSION CRITERIA - RECIPIENT:
- •Age >= 4 years
- •T-cell proliferation and/or dysregulation (TCP/D) deemed to be of sufficient past severity to warrant hematopoietic cell transplantation (HCT) that meets at least one of the criteria below:
- •Identified germline T-cell activating mutation in the phosphoinositide 3-kinase (PI3k) pathway
- •Identified adenosine deaminase 2 (ADA2) deficiency (biallelic mutations in CECR1 (ADA2) and/or phenotypically with low ADA2 level) leading to neutropenia requiring chronic granulocyte colony-stimulating factor (GCSF) therapy or to transfusion-dependent anemia or thrombocytopenia
- •T-cell infiltration of liver, spleen, lymph nodes, marrow, lungs, gut, or other organs by T cells, as evidenced by laboratory, radiographic, and/or anatomic pathology evaluation, resulting in organ dysfunction and/or organomegaly
- •Latent herpesvirus infection in T lymphocytes
- •History of or active evidence of hemophagocytic lymphohistiocytosis (HLH)
- •Recurrent or prolonged fevers attributed to immune dysregulation
- •T-cell population in blood and/or marrow with immunophenotype of large granular lymphocytes (LGL), with or without clonality or lymphocytosis
- •T-cell lymphoproliferative disorder in the setting of an underlying immune defect
- •Immune-mediated cytopenias of one lineage requiring transfusion or GCSF support or of 2 or 3 lineages with or without transfusion or support
- •Chronic active Epstein-Barr virus (EBV)
- •At least one potential 7-8/8 human leukocyte antigen (HLA)-matched related (excluding an identical twin) or unrelated donor (at HLA-A, -B, -C, and -DR), or an HLA-haploidentical related donor, based on initial low resolution unrelated donor search and/or at least one biologically- related family member who has at least a 25% chance of being at minimum an HLA- haploidentical match and is potentially suitable to donate based on reported family history. HLA typing of potential donors and/or mutation testing does not need to be completed for eligibility.
- •Adequate end-organ function, as measured by:
- •Left ventricular ejection fraction (LVEF) greater than or equal to 40% by 2-dimensional (2D) echocardiogram (ECHO) or left ventricular shortening fraction greater than or equal to 20% by ECHO for subjects receiving reduced-intensity conditioning (RIC), or LVEF greater than or equal to 30% if the subject has radiologic evidence of aortic, renal, or coronary artery vasculitis. LVEF greater than or equal to 30% for subjects receiving immunosuppression-only conditioning (IOC).
- •Pulmonary function tests: diffusing capacity of the lungs for carbon monoxide (DLco) (corrected for hemoglobin) and forced expiratory volume (FEV1) greater than or equal to 40% of predicted for the RIC arm, and greater than or equal to 30% predicted for the IOC arm; or in pediatric subjects, if unable to perform pulmonary function tests, there should be no evidence of dyspnea at rest, no requirement for supplemental oxygen, and oxygen saturation >92% on room air. Calculations will be based on the values reported in (Clinical Research Information System (CRIS).
- •Bilirubin <= 3.0 mg/dL (unless due to Gilbert's syndrome or hemolysis) for subjects receiving RIC and bilirubin <= 5.0 mg/dL for subjects receiving IOC (unless due to Gilbert's syndrome or hemolysis); alanine aminotransferase (ALT) and aspartate aminotransferase (AST) <= 5 x upper limit of normal (ULN) for subjects receiving RIC or <= 10 x ULN for subjects receiving IOC. Subjects who are above these bilirubin, ALT, or AST thresholds may be eligible for the RIC or IOC arm if evaluated by a hepatologist who deems the liver function test abnormalities to be potentially reversible with HCT.
- •Estimated creatinine clearance of >= 50 mL/min/1.73 m^2, calculated using estimated glomerular filtration rate (eGRF) in the clinical lab for adults and the Schwartz formula for pediatric subjects, if eGFR not reported by the clinical lab.
- •Karnofsky (adults) or Lansky (children) performance status of >= 50% or Eastern Cooperative Oncology Group (ECOG) performance status of 2 or less for the RIC arm and >=30% or ECOG performance status of 3 or less for the IOC arm
- •Ability of subject or parent/legal guardian or Legally Authorized Representative (LAR) (e.g., in cases of adults unable to consent) to understand and the willingness to sign a written informed consent document
- •Not pregnant or breastfeeding. As therapeutic agents used in this trial may be harmful to a fetus, women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for at least one-year post-allo HCT. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in the study, she should inform her treating physician immediately.
- •Disease status: Subjects with lymphoproliferative disorder (LPD), large granular lymphocytic leukemia (LGL), hemophagocytic lymphohistiocytosis (HLH), or other TCP/D disorders requiring standard therapies to prepare for HCT should be referred in remission if possible. However, these diseases are often aggressive and require swift evaluation for HCT while concurrently attempting to establish disease control through the administration of standard therapies. If ongoing therapy for the underlying disease outside of the National Institutes of Health (NIH) is not in the best interest of the subject according to the clinical judgment of the principal investigator (PI), then the subject may receive standard treatment for his/her underlying TCP/D disorder as a bridge to HCT on this protocol, prior to starting the research phase of the study. If it becomes apparent that the subject will not be able to proceed to HCT, then he/she must come off study. Subjects receiving standard therapy will be told about the therapy, associated risks, potential benefits, alternatives to the proposed therapy, and the availability of receiving the same treatment elsewhere, outside of a research protocol.
排除标准
- •RECIPIENT:
- •Subjects who are receiving any other investigational agents, with the exception of virus- specific cytotoxic T-cells for the treatment of viral infection/reactivation prior to allo HCT.
- •Prohibitive allergy to a study drug or to compounds of similar chemical or biologic composition of the agents (equine anti-thymocyte globulin (e-ATG), steroids, cyclophosphamide, busulfan, pentostatin, tacrolimus, mycophenolate mofetil (MMF), G-CSF) used in the study.
- •Active psychiatric disorder which is deemed by the PI to have significant risk of compromising compliance with the transplant protocol, or which does not allow for appropriate informed consent
- •Human immunodeficiency virus (HIV) positive or other acquired immunodeficiency that, as determined by the PI, interferes with the assessment of TCP/D severity and/or the attribution of clinical manifestations of immunodeficiency to a disorder of TCP/D.
- •Magnesium Transporter 1 (MagT1) mutation and active need to take anti-platelet agents and/or therapeutic anti- coagulation that cannot be interrupted during aplasia
- •Lack of adequate central venous access potential
- •INCLUSION CRITERIA RELATED DONOR
- •Age greater than or equal to 4 years
- •Related donor deemed suitable and eligible, and willing to donate, per clinical evaluations who are additionally willing to donate blood, urine, and marrow specimens for research. Related donors will be evaluated in accordance with existing Standard Policies and Procedures for determination of eligibility and suitability for clinical donation. Note that participation in this study is offered to all related donors, but is not required for clinical donation, so it is possible that not all related donors will enroll onto this study.
- •EXCLUSION CRITERIA - RELATED DONOR:
- •INCLUSION CRITERIA - UNRELATED DONOR:
- •Unrelated donors will be evaluated in accordance with existing National Marrow Donor Program (NMDP) Standard Policies and Procedures, available at: http://bethematch.org/About-Us/Global- transplant-network/Standards/, except for the additional requirement of EBV serostatus testing for clinical purposes of donor selection. Note that participation in this study is offered to all unrelated donors but not required for clinical donation, so it is possible that not all unrelated donors will enroll on this study. Unrelated donors only enroll if they contribute research specimens, which is optional.
- •EXCLUSION CRITERIA - UNRELATED DONOR:
- •Unrelated donors: failure to qualify as a National Marrow Donor Program (NMDP) donor per current NMDP Standards, available at: http://bethematch.org/About-Us/Global-transplant-network/Standards/. Exceptions to donor eligibility (e.g. foreign travel, tattoos) do not automatically exclude the donor and will be reviewed by the PI.
研究组 & 干预措施
Arm 1/Reduced-Intensity Conditioning (RIC)
Reduced Intensity Conditioning Arm.
干预措施: Allogeneic HSC (Procedure)
Arm 1/Reduced-Intensity Conditioning (RIC)
Reduced Intensity Conditioning Arm.
干预措施: Bisulfan (Drug)
Arm 1/Reduced-Intensity Conditioning (RIC)
Reduced Intensity Conditioning Arm.
干预措施: e-ATG (Drug)
Arm 2/Immunosuppression-only Conditioning (IOC)
Immunosuppression Only Conditioning Arm.
干预措施: Prednisone (Drug)
Arm 1/Reduced-Intensity Conditioning (RIC)
Reduced Intensity Conditioning Arm.
干预措施: Immunosuppression Only Conditioning (Procedure)
Arm 2/Immunosuppression-only Conditioning (IOC)
Immunosuppression Only Conditioning Arm.
干预措施: Bisulfan (Drug)
Arm 1/Reduced-Intensity Conditioning (RIC)
Reduced Intensity Conditioning Arm.
干预措施: Reduced Intensity Conditioning (Procedure)
Arm 1/Reduced-Intensity Conditioning (RIC)
Reduced Intensity Conditioning Arm.
干预措施: GVHD Prophylaxis (Drug)
Arm 1/Reduced-Intensity Conditioning (RIC)
Reduced Intensity Conditioning Arm.
干预措施: Prednisone (Drug)
Arm 1/Reduced-Intensity Conditioning (RIC)
Reduced Intensity Conditioning Arm.
干预措施: Cyclophosphamide (Drug)
Arm 1/Reduced-Intensity Conditioning (RIC)
Reduced Intensity Conditioning Arm.
干预措施: MMF (Drug)
Arm 1/Reduced-Intensity Conditioning (RIC)
Reduced Intensity Conditioning Arm.
干预措施: Mesna (Drug)
Arm 1/Reduced-Intensity Conditioning (RIC)
Reduced Intensity Conditioning Arm.
干预措施: Tacrolimus (Drug)
Arm 1/Reduced-Intensity Conditioning (RIC)
Reduced Intensity Conditioning Arm.
干预措施: Pentostatin (Drug)
Arm 1/Reduced-Intensity Conditioning (RIC)
Reduced Intensity Conditioning Arm.
干预措施: PFTs (Diagnostic Test)
Arm 1/Reduced-Intensity Conditioning (RIC)
Reduced Intensity Conditioning Arm.
干预措施: DEXA (Diagnostic Test)
Arm 1/Reduced-Intensity Conditioning (RIC)
Reduced Intensity Conditioning Arm.
干预措施: Bone Marrow Aspirate & Biopsy (Procedure)
Arm 1/Reduced-Intensity Conditioning (RIC)
Reduced Intensity Conditioning Arm.
干预措施: EKG (Diagnostic Test)
Arm 1/Reduced-Intensity Conditioning (RIC)
Reduced Intensity Conditioning Arm.
干预措施: 2D ECHO (Diagnostic Test)
Arm 2/Immunosuppression-only Conditioning (IOC)
Immunosuppression Only Conditioning Arm.
干预措施: e-ATG (Drug)
Arm 2/Immunosuppression-only Conditioning (IOC)
Immunosuppression Only Conditioning Arm.
干预措施: Immunosuppression Only Conditioning (Procedure)
Arm 2/Immunosuppression-only Conditioning (IOC)
Immunosuppression Only Conditioning Arm.
干预措施: GVHD Prophylaxis (Drug)
Arm 2/Immunosuppression-only Conditioning (IOC)
Immunosuppression Only Conditioning Arm.
干预措施: Allogeneic HSC (Procedure)
Arm 2/Immunosuppression-only Conditioning (IOC)
Immunosuppression Only Conditioning Arm.
干预措施: Cyclophosphamide (Drug)
Arm 2/Immunosuppression-only Conditioning (IOC)
Immunosuppression Only Conditioning Arm.
干预措施: MMF (Drug)
Arm 2/Immunosuppression-only Conditioning (IOC)
Immunosuppression Only Conditioning Arm.
干预措施: Mesna (Drug)
Arm 2/Immunosuppression-only Conditioning (IOC)
Immunosuppression Only Conditioning Arm.
干预措施: Tacrolimus (Drug)
Arm 2/Immunosuppression-only Conditioning (IOC)
Immunosuppression Only Conditioning Arm.
干预措施: Pentostatin (Drug)
Arm 2/Immunosuppression-only Conditioning (IOC)
Immunosuppression Only Conditioning Arm.
干预措施: PFTs (Diagnostic Test)
Arm 2/Immunosuppression-only Conditioning (IOC)
Immunosuppression Only Conditioning Arm.
干预措施: DEXA (Diagnostic Test)
Arm 2/Immunosuppression-only Conditioning (IOC)
Immunosuppression Only Conditioning Arm.
干预措施: Bone Marrow Aspirate & Biopsy (Procedure)
Arm 2/Immunosuppression-only Conditioning (IOC)
Immunosuppression Only Conditioning Arm.
干预措施: EKG (Diagnostic Test)
Arm 2/Immunosuppression-only Conditioning (IOC)
Immunosuppression Only Conditioning Arm.
干预措施: 2D ECHO (Diagnostic Test)
Arm 3/Donor
Healthy Donor- Donors for recipients in arm 1 or arm 2.
结局指标
主要结局
Percentage of Recipients Who Are Alive With >50% Donor T Cell Chimerism and Graft-failure Free at 180 Days Post Hematopoietic Cell Transplant (HCT) Reported With an 80% Confidence Interval
时间窗: Day +180 post-HCT
Percentage of recipients with \> 50% donor T cell chimerism and without death or graft failure. A graft failure event is defined as either primary or secondary graft failure, in the absence of a recurrent marrow malignancy.
Percentage of Recipients Who Are Alive With >50% Donor T Cell Chimerism and Graft-failure Free at 180 Days Post Hematopoietic Cell Transplant (HCT) Reported With a 95% Confidence Interval
时间窗: Day +180 post -HCT
Percentage of recipients with \> 50% donor T cell chimerism and without death or graft failure. A graft failure event is defined as either primary or secondary graft failure, in the absence of a recurrent marrow malignancy.
次要结局
- Cumulative Incidence of Transplant-related Mortality(Day +180, and 1-year post-transplant)
- Cumulative Incidence of Secondary Graft Failure(1-, 3-, and 5-years post-transplant)
- Percent Probability of Overall Survival (OS)(1-, 3-, and 5-years post-transplant)
- Percentage of Participants Who Achieve Chimerism at Stated Days Between Those Who Have Failed by Day 60 or Have Not(Day +21, +28, +35, +42, and +60 after hematopoietic cell transplant (HCT))
- Percentage of Donor T-cell Populations at Days +28, +42, +60, +100, +180, and 1-year Post Hematopoietic Cell Transplant (HCT)(Days +28, +42, +60, +100, +180, and 1-year post hematopoietic cell transplant)
- Cumulative Incidence of Chronic Graft-versus-host Disease (cGVHD)(1 and 2-years post-transplant)
- Cumulative Incidence of Acute Graft-versus-host Disease (aGVHD) at 1 Year(1-year post-transplant)
- Percent Probability Event-free Survival (EFS)(1, 3, and 5-years post-transplant)
- Cumulative Incidence of Primary Graft Failure at Day +60(Day +60)
- Percentage of Participants With Lymphoproliferative Disease/Lymphoma Relapse at 1, 3, and 5-years Post-hematopoietic Cell Transplant (HCT)(1, 3, and 5 years post-HCT)
- Percent Probability Graft Versus Host Disease (GVHD)-Free Graft Failure-free Survival (GGFS)(1, 3, and 5 years post-hematopoietic cell transplant (HCT))
- Percent Probability of Graft Versus Host Disease (GVHD)-Free Relapse-free Survival (GRFS)(1, 3 and 5-years post-hematopoietic cell transplant (HCT))
- Cumulative Incidences of Cytomegalovirus (CMV), BK Virus (BK), Adenovirus, Human Herpes Virus 6 (HHV6), JC Virus (JCV), and Epstein-Barr Virus (EBV) Detection in Blood at Day +100 Post-HCT(day +100 post-HCT)
- Percentage of Donor B-cell Populations at Days +28, +42, +60, +100, +180, and 1-year Post-transplant(Days +28, +42, +60, +100, +180, and 1-year post-transplant)
- Percentage of Donor Natural Killer (NK-) Cell Populations at Days +28, +42, +60, +100, +180, and 1-year Post Transplant(Days +28, +42, +60, +100, +180, and 1-year post transplant)
- Percentage of Donor Myeloid Cell Populations at Days +28, +42, +60, +100, +180, and 1-year Post Transplant(Days +28, +42, +60, +100, +180, and 1-year post transplant)
研究者
Dimana Dimitrova
Principal Investigator
National Cancer Institute (NCI)